Corey Goodman
Managing Partner @ venBio Partners
San Francisco, United States
Corey Goodman is a renowned scientist, entrepreneur, educator, CEO, and corporate executive. Goodman is Founding Partner of venBio, Adjunct Professor at the University of California, San Francisco, and Chair of the Board of Directors of Limerick BioPharma, Second Genome, Oligasis, and Ossianix, and member of the Board of NeuroTherapeuticsPharma. He is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. Goodman was previously President of Pfizer's Biotherapeutics and Bioinnovation Center and a member of its Executive Leadership Team. He is a co-founder of Exelixis, Renovis, and Second Genome, and served as CEO of Renovis prior to its acquisition. Goodman is also a member of the California Council on Science and Technology, the Pacific Institute, the Board of the McKnight Endowment Fund for Neuroscience, BayBio, Biotechnology Institute, Bay Area Science and Innovation Consortium, New York Stem Cell Foundation, QB3 (UCSF-UCB-UCSC) Industry Advisory Board, Stanford's BioX Biosciences Advisory Council, Spinal Muscular Atrophy Foundation, and is former Chair of the National Research Council's Board on Life Sciences. During his academic career, Goodman spent over two decades as a professor of biology and neuroscience at Stanford and U.C. Berkeley, and earning numerous scientific awards such as the Alan T. Waterman Award from the National Science Board, the Gairdner International Award for Achievement in Medical Sciences, and the March-of-Dimes Prize in Developmental Biology. Goodman received his B.S. from Stanford University, Ph.D. from U.C. Berkeley, and was a postdoctoral fellow at U.C. San Diego.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Corey Goodman invests in
Stages Corey Goodman invests in
Countries Corey Goodman invests in
Investment Focus
Industry
- Biotechnology 7 (35%)
- Health Care 5 (25%)
- Therapeutics 4 (20%)
- Pharmaceutical 4 (20%)
- Life Science 3 (15%)
Stage
- Series A 4 (20%)
- Series C 4 (20%)
- Seed 3 (15%)
- Series D 2 (10%)
- Series E 2 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Parabilis Medicines
|
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M / Series F / Jan 08, 2026 | |
FogPharma
|
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together withworld-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years. | $145M / Series E / Mar 01, 2024 | |
|
Parabilis Medicines
|
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $145M / Series E / Mar 01, 2024 | |
Insamo
|
Insamo offers the discovery of membrane-permeable & orally available cyclic-peptides which lies in its automated process of designing, synthesizing, and testing at an unprecedented scale. | $12M / Seed / Feb 21, 2024 | |
|
FogPharma
|
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together withworld-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years. | $178M / Series D / Nov 21, 2022 | |
|
Parabilis Medicines
|
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $178M / Series D / Nov 21, 2022 | |
MindRhythm
|
MindRhythm is a medical device company focused on applying novel biometrics to stroke and concussion patients to improve diagnosis, triage and management. Their proprietary monitoring devices and communication platform provide novel and real-time visibility to life-threatening situations prehospital and in the operating room, allowing clinicians tointervene earlier and with better precision to prevent brain damage. | $5M / Seed / Aug 24, 2021 | |
|
FogPharma
|
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together withworld-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years. | $107M / Series C / Jan 11, 2021 | |
|
Parabilis Medicines
|
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $107M / Series C / Jan 11, 2021 | |
Tallac Therapeutics
|
Tallac Therapeutics offers next-generation immunotherapies for cancer patients. The company is based in Burlingame, California. | $62M / Series A / Dec 01, 2020 | |
| See all 20 investments → | |||
Co-Investors
About venBio Partners
venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams.We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet theirrequirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.
venBio Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Behzad Aghazadeh
Managing Team
|
|||
|
Corey Goodman
Managing Partner
|
|||
Richard Gaster
Managing Partner
|
|||
Robert Adelman
Managing Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Corey Goodman invest in?
Corey Goodman invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Corey Goodman last invest?
The most recent investment recorded for Corey Goodman closed in Jan 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
